.
MergerLinks Header Logo

Announced

Completed

Koch Disruptive Technologies led a $215m Series B round in Immunai.

Financials

Edit Data
Transaction Value£156m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Minority

Friendly

Completed

Domestic

United States

Private Equity

Venture Capital

Single Bidder

biotechnology company

Private

Biotechnology

Acquisition

Synopsis

Edit

Koch Disruptive Technologies led a $215m Series B round in Immunai, a New York-based biotech company, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US